share_log

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product

バイオテクノロジーの日々: ニューロクライン、エディタスの候補に対するFDAオーファンドラッグタグ、ブリッジバイオのPRVの販売、PolarityTEの製品のRMAT指定

Benzinga Real-time News ·  2022/05/13 10:43

Here's a roundup of top developments in the biotech space over the last 24 hours:

Stocks In Focus

Switzerland Approves Moderna's COVID-19 Shot For Kids 6-11

The Swiss drug regulatory authority has approvedModerna Inc's(NASDAQ:MRNA) COVID-19 vaccine for children ages 6-11.

The approval is for the vaccine's two-dose series of 50 micrograms per dose, Moderna added.

Shares were up 6.72% at $138.92 Friday.

Neurocrine's Huntington's Candidate Secures FDA Orphan Drug Tag

The FDA has granted Orphan Drug Designation toNeurocrine Biosciences Inc's(NASDAQ:NBIX) valbenazine for Huntington's disease (HD).

The treatment of chorea associated with...

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする